Hudson Bay Capital Management LP Merus N.V. Transaction History

Hudson Bay Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$28.03 - $51.82 $1.74 Million - $3.22 Million	-62,200 Reduced 71.33%	25,000 $1.13 Million
Q4 2023 Feb 14, 2024	SELL	$20.06 - $28.66 $1.62 Million - $2.31 Million	-80,618 Reduced 48.04%	87,200 $2.4 Million
Q3 2023 Nov 14, 2023	BUY	$20.13 - $27.29 $1.74 Million - $2.36 Million	86,512 Added 106.4%	167,818 $3.96 Million
Q2 2023 Aug 14, 2023	BUY	$18.33 - $27.18 $1.49 Million - $2.21 Million	81,306 New	81,306 $2.14 Million

197

62M

124K

208K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.